What You Should Know:
– Weave Bio, the leader in AI-native regulatory automation, today announced the launch of HAQ Manager, a breakthrough capability that applies artificial intelligence (AI) and workflow automation to accelerate responses to Health Authority Questions (HAQs) during regulatory review.
– This launch extends Weave’s platform beyond submission preparation into the critical post-submission review phase, helping organizations navigate one of the most time-pressured and consequential stages of drug development.
Weave Bio Launches HAQ Manager to Accelerate Regulatory Response Workflows with AI
Weave Bio, an AI-native software company redefining how therapies progress from lab to market, has introduced HAQ Manager, an advanced AI solution designed to streamline health authority question (HAQ) responses across the regulatory lifecycle. Developed in close collaboration with Takeda Pharmaceuticals, HAQ Manager automates one of the most time-sensitive and complex phases of the regulatory process—responding to FDA, EMA, and global agency inquiries with precision, speed, and full compliance.
Built into The Weave Platform, HAQ Manager automatically extracts and categorizes incoming agency questions, drafts responses using verified source data and historical regulatory context, and unifies contributions across teams for final submission. Intelligent workflow automation ensures real-time collaboration, version control, and alignment across regulatory, operational, and scientific functions—empowering teams to deliver consistent, high-quality responses under tight deadlines.
“When health authorities have questions, every hour counts,” said Brandon Rice, Co-Founder and CEO of Weave Bio. “HAQ Manager brings the same AI-driven efficiency our customers rely on for submissions to one of the most critical stages of the regulatory lifecycle. By automating administrative complexity and surfacing the right information at the right time, we give regulatory teams the speed and confidence they need to respond decisively while maintaining accuracy and compliance.”
The launch follows Weave Bio’s $20 million Series A funding round and marks another milestone in its mission to transform end-to-end regulatory operations. Initially recognized as the “Biotech AI Innovation of the Year” for its transformative impact on preclinical IND preparation, The Weave Platform has since evolved into a comprehensive AI workbench supporting clinical-stage submissions. The platform now accelerates regulatory timelines by over 50%, enhances review quality, and ensures adherence to FDA, EMA, and international standards.
By extending its capabilities to the post-submission phase, HAQ Manager complements Weave’s growing suite of regulatory automation tools spanning preclinical through clinical development. Future expansions will include support for New Drug Applications (NDAs), Biologics License Applications (BLAs), postmarket filings, and extended coverage for markets in Europe, Japan, and Latin America.
Through its fully integrated, AI-powered infrastructure, Weave Bio continues to advance a unified vision of regulatory excellence—enabling life sciences organizations to navigate the path to approval faster, smarter, and with greater confidence than ever before.
